Depression has repeatedly been linked to subclinical hypothyroidism, and thyroid hormones have successfully been used to augment antidepressant treatment. By contrast, the extent of thyroid dysfunction in anxiety disorders remains less clear. This is surprising, given that anxietyrelated symptoms (e.g., nervousness, palpitations, increased perspiration) are highly prevalent in hyperthyroidism. The present study was undertaken to synthesize the literature on hypothalamic-pituitary-thyroid (HPT) axis functioning in anxiety disorders. The PubMed and PsycINFO databases were systematically searched. Three types of studies were included: (1) "comorbidity studies" assessing the prevalence of thyroid disorders in individuals with anxiety disorders, (2) "case-control studies" comparing HPT parameters between patients and controls, and (3) "correlational studies" assessing self-reported anxiety levels and HPT parameters. Risk of bias was assessed via a standardized quality rating. Twenty studies were eligible. Nearly all found the comorbidity between anxiety and thyroid disorders was significant. Half of the studies additionally supported the notion of subtle thyroid dysfunction in that thyroid-stimulating hormone (TSH) responses to the administration of thyrotropin-releasing hormone (TRH) were blunted and an inverse relationship was observed between self-reported anxiety levels and TSH. Overall, HPT assessments were well conducted, but several studies failed to adjust their analyses for smoking, 
INTRODUCTION
For decades, the hypothalamic-pituitary-thyroid (HPT) axis has been subject to investigation in depressive disorders (Fountoulakis et al., 2006 ). An impetus for this line of research to evolve was that patients with overt hypothyroidism exhibit symptoms that overlap with those of major depression (Feldman, Shrestha, & Hennessey, 2013) . This is not surprising, given the widespread expression of thyroid hormone receptors in almost all bodily tissues, including the brain (Bauer, Goetz, Glenn, & Whybrow, 2008) . Subsequent research has revealed that, conversely, some patients with depressive disorders seem to be characterized by subclinical forms of hypothyroidism (Fountoulakis et al., 2006) . Correspondingly, triiodothyronine (T3) has successfully been used as an augmentation strategy in depressed patients who were resistant to standard first line treatments, such as antidepressants (Cleare et al., 2015) .
By contrast, far less research has been dedicated to studying HPT functioning in anxiety disorders. As with depression, some of the most important anxiety symptoms are mimicked by thyroid disorders. For instance, patients with overt hyperthyroidism frequently report anxiety, fatigue, poor concentration, and disturbed sleep, all of which constitute core symptoms of generalized anxiety disorder (GAD; De Leo, Lee, & Braverman, 2016) . In addition, a number of somatic symptoms, such as palpitations, shortness of breath, and increased perspiration overlap with what patients with panic disorder (PD) experience during panic attacks. The reverse, namely the extent of thyroid dysfunction as present in patients with anxiety disorders, however, still remains unclear. Learning more about such dysfunction would first mean to obtain an estimate of the presence of (subclinical) thyroid disorders in patients with anxiety disorders. Second, it would imply to study subtle alterations in individual HPT parameters, that is, thyrotropinreleasing hormone (TRH), thyroid-stimulating hormone (TSH), and the thyroid hormones T3, and thyroxine (T4), as has been done in depression. Doing so may shed light on the intricate relationship between anxiety and HPT functioning and could help to determine whether the above listed anxiety symptoms may emerge as an epiphenomenon of subclinical thyroid dysfunction, too.
In their narrative review of this literature, Simon et al. (2002) found initial support for an increased prevalence of thyroid disorders in patients with GAD and PD. However, as noted by the authors, at the time when their review was published, no community or primary care
studies were yet available, and the authors therefore had to rely on a number of relatively small secondary and tertiary care studies, which likely suffered from selection bias. In addition, sufficiently sensitive kits to determine TSH were only developed between 1980 and 1990, which may have rendered it impossible for some of the included studies to detect subclinical thyroid dysfunction (nine of the 13 included studies were published before 1990). Finally, very few data on subtle alterations in the HPT axis were available, which may be gained from studies comparing patients' resting or stimulated thyroid parameters with those of healthy controls.
The present study was therefore undertaken to update and extend this previous review by systematically searching and synthesizing the literature on HPT functioning in anxiety disorders. Our specific aims were threefold: (1) to investigate whether patients with anxiety disorders have an increased risk of (subclinical) thyroid disorders, (2) to find out whether the same patients are characterized by subtle alterations in thyroid parameters when compared to controls, and (3) to determine whether there is a continuous relationship between anxiety levels and thyroid parameters. Based on their symptom profiles and on the previous literature review by Simon et al. (2002) , we mainly expected studies using patients with GAD, PD, and social anxiety disorder (SAD) to have investigated and revealed abnormalities in HPT functioning.
METHODS

Search strategy
Potentially relevant records were identified by systematically searching the PubMed and PsycINFO databases from 1990 until February 2017. Key words and subject headings were selected in accordance with the thesaurus of each database. The search string consisted of two components: (1) "anxiety disorder," including synonyms and related terms and (2) "thyroid" and synonyms and related terms. Both searches were confined to studies conducted in humans. No language restrictions were applied, but one study was later excluded because it was written in Russian.
Screening and study selection procedure
Three types of studies were to be included. The first type were "comorbidity studies" assessing the prevalence of thyroid disorders in individuals with anxiety disorders and/or their comorbidity in apparently healthy individuals of the general population. The second type were "case-control studies" comparing HPT parameters between patients with anxiety disorders and patients with other mental disorders or healthy controls. Anxiety disorders comprised all categories contained in the relevant DSM-5 chapter (APA, 2013) and applying to adults, namely specific phobia, SAD, PD, agoraphobia, and GAD, and had to be diagnosed according to DSM-III-R (APA, 1987) , DSM-IV (APA, 2000) , DSM-5 (APA, 2013 ), or ICD-10 criteria (WHO, 1992 . The third type were "correlational studies" assessing self-reported anxiety levels (using a validated questionnaire) and HPT parameters in patients with any of the above anxiety disorders or in apparently healthy individuals of the general population. Abiding by these inclusionary criteria meant that studies confined to specific populations (e.g., pregnant women) were excluded, and so were studies exclusively looking at patients with obsessive-compulsive disorder or posttraumatic stress disorder. Comorbidity with mental or somatic illnesses, however, was allowed, and so was the current intake of medication, but this was recorded. Full-text articles were retrieved and checked for relevant results. The reference sections of all articles were manually searched for additional records.
Data extraction
For each identified study, two members of the study team collected information about the authors, year of publication, the sample and setting, eligibility criteria, diagnostic procedures for the anxiety disorder, measurement of self-reported anxiety levels, diagnostic procedures for thyroid disorders, assessment of thyroid parameters, and the main study results.
Risk of bias was assessed by means of a modified version of a quality rating scale that was first used in a meta-analysis on cortisol in functional somatic syndromes (Tak et al., 2011) and on cortisol in predicting treatment response in anxiety and depressive disorders Fischer, Strawbridge, Herane Vives, & Cleare, 2017) .
We adapted five of the original items (some were excluded due to nonapplicability) to match the present research question and scored them using the original three-point scale (0-2). The complete checklist can be found in Table 1 . Depending on whether a control group was included in the study or not, the maximum attainable quality score was between 8 and 10.
RESULTS
Search results
The search yielded 1,594 records, of which 38 were considered potentially relevant for the present research question based on their title or abstract. Of these, 18 studies were excluded due to the following reasons: they were not conducted in patients with a primary diagnosis of an anxiety disorder, did not diagnose anxiety disorders in accordance with DSM or ICD criteria, were single-case studies, did not assess thyroid functioning, or did not report relevant results. In total, 20 studies were eligible for data extraction.
TA B L E 1 Quality rating scale to assess risk of bias in studies investigating the relationship between Hypothalamic-Pituitary-Thyroid (HPT) functioning and anxiety (Disorders); Items modified from , Tak et al. (2011), and (1) What eligibility criteria were used?
Nonclinical samples: Representative sample of the general population (2) Community or primary care sample (0)
Clinical samples:
Regulated iodine intake, no comorbidity with major somatic diseases, no comorbidity with major mental disorders, no current medication use, 3-4 used (2) Regulated iodine intake, no comorbidity with major somatic diseases, no comorbidity with major mental disorders, no current medication use, 1-2 used (1) Regulated iodine intake, no comorbidity with major somatic diseases, no comorbidity with major mental disorders, no current medication use, 0 used or not clearly stated (0) Tables 2-4 show the characteristics of all 20 included studies. Ten studies evaluated how frequently thyroid disorders were present in patients with anxiety disorders (comorbidity studies), nine compared thyroid parameters between patients with anxiety disorders and controls (case-control studies) and seven correlated self-reported anxiety levels with thyroid parameters (correlational studies). More detailed study characteristics are provided in the corresponding sections below.
Study characteristics
Risk of bias
Depending on whether a control group was included in the study or not, the maximum attainable quality score was between 8 and 10. The average score was 3 ± 1 (standard deviation; SD) for studies with a maximum score of 8 (range: 2-5) and 5 ± 2 for studies with a maximum score of 10 (range: 3-8). This difference in means was mainly due to the fact that almost all of the latter studies scored points on the extra item for carefully selecting their control group. Across all studies, the highest scores were obtained for how hormonal assessments of the HPT axis were conducted, including the diagnostic procedures for establishing thyroid disorders as well as the handling of samples to determine thyroid parameters (item 3). By contrast, only one study reported whether the assessors of anxiety were blind to thyroid status (item 4) and many studies failed to adjust their statistical analyses for relevant trait-like confounders (item 5). More specifically, only two studies controlled for smoking, three for body mass index (BMI), and eight for depression. Age and sex, by contrast, were controlled for by the majority of studies.
Comorbidity studies: Thyroid disorders in patients with anxiety disorders
Ten studies in total contained comorbidity analyses (see Table 2 ), using samples from the United States, South America, Europe, and Australia.
Of these, four were conducted in community samples, whereas the other six used outpatients. All four community studies found significant relationships between the presence of anxiety disorders and the presence of thyroid disorders, the latter established by questionnaires, medical interviews, physical examination, and/or laboratory testing.
However, one of these studies later failed to replicate their positive finding in an independent sample of slightly older adults (Witthauer
TA B L E 2
Characteristics of included studies assessing the prevalence of thyroid disorders in patients with anxiety disorders (comorbidity studies)
Study
Sample
Anxiety disorder
Thyroid disorder
Main results
Quality assessment Noyes et al. (1992) et al., 2016) . All six outpatient studies mainly included patients with PD. The prevalence of any thyroid disorder in these patients ranged from 2.2 to 39.3%, with some studies relying on medical histories to obtain diagnoses and others measuring thyroid parameters and using cut-off values. Two of these studies compared patients with different types of anxiety disorders with each other. Both found that patients with GAD had the highest prevalence of comorbid thyroid disorders.
Unfortunately, none of the comorbidity studies separated results into subclinical and overt forms of thyroid disorders. Although most studies did not report which thyroid disorders they assessed, one study found hypothyroidism to be more common in PD (Gloger, Fardella, Santis, & Bitran, 1997) , whereas another showed hyperthyroidism to prevail in the same patients (Fardella et al., 2000) .
Case-control studies: Thyroid parameters in patients with anxiety disorders and controls
Nine studies included case-control comparisons (see Table 3 ). These studies were conducted in the United States, South America, and
Europe. Most studies exclusively used outpatients with PD and all excluded patients with a history of thyroid disorders or any current somatic disease (including overt thyroid disorders). In terms of resting HPT parameters, none of the studies found any differences in cerebrospinal TRH, plasma/serum TSH, T3, free T4, or T4 when contrasting patients with healthy controls. One study compared patients with PD to patients with depressive disorders and found that the former group had higher fT4 levels (Fardella et al., 2000) . A more complex picture emerged when focusing on stimulated thyroid parameters, in this case TSH after a 400-500 g TRH challenge. These challenges were conducted to test the integrity of the HPT axis, and most authors expected attenuated responses based on previous findings in depressed patients. Of the four studies, two indeed showed blunted responses in patients when compared to healthy controls, whereas the other two could not detect any differences (continuous analyses).
When separating patients and controls into normal versus abnormal responders (cutoff of 5 or 7 U/ml), again two out of the four studies found that patients more often fell into the abnormal responder category. Overall, three of the four studies reported some evidence for attenuated TSH responses in anxious patients, be it based on continuous or categorical analyses.
Correlational studies: Self-reported anxiety levels and thyroid parameters
Seven studies correlated self-reported anxiety levels with thyroid parameters (see Table 4 ). These studies were conducted in the United
States, Europe, and Japan. The settings included general population based samples, primary care samples, outpatient and inpatient samples. The one general population based sample split participants into those with versus without current T4 intake and found a positive relationship between TSH and anxiety levels in medicated and a negative relationship in unmedicated individuals (Panicker et al., 2009 ). The latter finding was confirmed in a large primary care sample of older patients (Roberts et al., 2006) , whereas an earlier study in a similar setting and using a small sample of younger females had failed to find such a link (Balada, Torrubia, & Arque, 1992) . Two of the four clinical studies showed no dose-response relationship between resting or stimulated thyroid parameters and anxiety levels, whereas the other two showed a negative association between THR-stimulated TSH, resting fT4, and anxiety levels in patients with PD.
DISCUSSION
The aim of this systematic review was to investigate the extent to which patients with anxiety disorders are affected by thyroid dysfunction. We report three main findings: First, patients with an anxiety disorder were significantly more likely to concomitantly have a thyroid disorder. Second, patients with PD and SAD did not differ from healthy controls in resting thyroid parameters, but half of the studies found evidence for attenuated TSH responses upon stimulation with TRH. Third, there was evidence for a negative relationship between self-reported anxiety and TSH levels.
The first finding is in line with the first and only available review of the literature that was published 15 years ago (Simon et al., 2002) , and This heterogeneity reflects ongoing controversies about the reference ranges for thyroid dysfunction and the general lack of consent in terms of diagnostic procedures (Chaker, Bianco, Jonklaas, & Peeters, 2017; De Leo et al., 2016) . Notably, the nature (hypothyroidism vs. hyperthyroidism) and severity (subclinical vs. overt) of the comorbid thyroid disorders remains unclear, as barely any of the studies reported this.
Moreover, there is a possibility that part of the observed comorbidity is due to the simultaneous presence of mood disorders, which were not always excluded or adjusted for. This is supported by the extremely high co-occurrence of GAD and mood disorders, which during the preparation of DSM-5 even led to suggestions of creating a category combining the two disorders (Goldberg, Kendler, Sirovatka, & Regier, 2010) . Finally, none of the studies was longitudinal, which means that the temporal order of this relationship could not be established. This is especially problematic seeing that cross-sectional research also shows that individuals with thyroid disorders have an increased probability of a concomitant anxiety disorder (e.g., Giynas, Uguz, Askin, & Gonen, 2014; Patten, Williams, Esposito, & Beck, 2006) . However, in the study of Sareen, Jacobi, Cox, Belik, Clara, and Stein (2006) and Witthauer et al. (2016) , using age-of-onset data, anxiety disorders were shown to precede the onset of thyroid disorders in the majority of cases, which could mean that subtle HPT axis alterations in anxious patients over time progress into subclinical and/or overt forms of thyroid disorders.
Further support for this notion may be gained from studies comparing HPT axis functioning between anxious patients and healthy controls-both free of any overt thyroid conditions. According to the present review, there is no difference in any resting HPT axis parameter between the two groups. This null finding could either reflect real absence of subtle basal abnormalities in patients or be the due to methodological problems with single time point measurements, which are more susceptible to the influence of state-like confounders. For instance, thyroid parameters are known to follow specific circannual and circadian rhythms (Kim et al., 2013; Russell et al., 2008) . Invariant sampling across seasons could thus have masked small group effects.
By contrast, the fact that the null finding was unanimous across studies with and without standardization of sampling schedules renders it unlikely for time of day to have superimposed group effects.
Results regarding stimulated TSH were equivocal, with half of the studies showing blunted responses to TRH challenge in anxious patients. All stimulation studies were remarkably homogeneous in the size of their sample and in their selection of patients: All used subjects in their mid-thirties, around half of which were women, and none of which had an overt thyroid disorder, were depressed, or currently using medication. There was more heterogeneity in terms of TRH administration and type of assay used, but none of these factors could explain the discrepant findings either. However, three out of four studies found some evidence for diminished TSH responses, either in continuous (peak TSH) or categorical (TRH nonresponders vs. responders)
analyses. One way to make sense of this is that an interaction of unre- Finally, a negative association between self-reported anxiety levels and TSH emerged in two very large samples of the general population.
This mirrors the first finding of significant comorbidity between anxiety disorders and thyroid disorders on a subclinical level. The results from patient samples, however, were inconclusive and need to be interpreted with caution, since they were often reported as part of a secondary analysis and most studies failed to adjust these for relevant confounders (hence the low-quality assessment scores).
There are different explanations for what may reside at the core of the co-occurrence between anxiety and alterations in the HPT axis. It is possible that the observed comorbidity is a mere artefact.
Heightened interoceptive sensitivity (Domschke, Stevens, Pfleiderer, & Gerlach, 2010) and intolerance of uncertainty (Carleton, 2012) are characteristic of many patients with anxiety disorders and may enhance the likelihood of being diagnosed with a thyroid disorder via increased healthcare seeking. This squares well with observations that individuals with subclinical forms of hyperthyroidism differ in the extent to which they experience and report symptoms (Cooper & Biondi, 2012) . However, this hypothesis is refuted by the fact that those studies diagnosing thyroid disorders through physical examinations and laboratory testing rather than by reviewing medical histories still found their presence significantly linked with anxiety disorders (Carta et al., 2004; Sareen et al., 2006) . Moreover, there was evidence for concomitant anxiety and HPT alterations on a subclinical level (case-control and correlational studies), again rendering this an unlikely scenario. Another explanation is common risk factors. Regular smoking and nicotine dependence is substantial in anxiety disorders (Morissette, Tull, Gulliver, Kamholz, & Zimering, 2007) and at the same time significantly increases the likelihood of developing overt hyperthyroidism, as present in Graves' disease (Wiersinga, 2013) . Against this, the two herein reviewed studies that controlled for smoking both still found the association between anxiety and thyroid dysfunction significant (Panicker et al., 2009; Sanna et al., 2013) . Finally, there is the explanation of partly shared etiopathogenetic mechanisms. Stressrelated long-term alterations in the hypothalamic-pituitary-adrenal (HPA) axis are present in some patients with anxiety disorders (Elnazer & Baldwin, 2014 ) and may at the same time foster autoimmunity via shifting of the Th1/Th2 immune balance (Elenkov, 2008; Montoro et al., 2009) . This is in line with evidence for psychosocial stress preceding the onset of Graves' disease, an autoimmune thyroid disorder (Bagnasco, Bossert, & Pesce, 2006) . Although the findings of the present review do not contradict this notion, they provide no direct support for it either. It is therefore upon future research to determine whether stress is indeed a contributor to the coexistence of anxiety and HPT abnormalities. This is the first systematic review of the literature on HPT axis functioning in anxiety disorders. Although we believe it useful in summarizing the current state of research and outlining pitfalls and promises of future research, a number of limitations need to be considered. First, albeit comprehensive, our search yielded relatively few studies that matched the a priori defined eligibility criteria. This points out the need for further research in this somewhat neglected area. Second, there was substantial methodological heterogeneity. For instance, studies varied in their use of DSM-III-R versus DSM-IV criteria, which in terms of the present review means that the six epidemiological studies diagnosing GAD included slightly different patient populations. Heterogeneity was further increased by our decision to consider and combine evidence from different types of studies (comorbidity, case-control, and correlational). Considering this heterogeneity, we did not think it sensible to undertake a meta-analysis to determine the strength of the anxiety-thyroid dysfunction association. Third, while the HPT axis assessments were properly conducted in most studies, the risk of bias review also revealed a number of methodological limitations.
For instance, despite excluding patients with a current major depressive episode, not all clinical studies assessed whether patients had a history of (hypo)manic episodes. Given the evidence for significant cooccurrence between PD and bipolar disorder (Vazquez, Baldessarini, & Tondo, 2014) , and for HPT alterations in at least some patients with bipolar disorders (e.g., Barbuti et al., 2017; Kleiner, Altshuler, Hendrick, & Hershman, 1999) , further case-control studies are advised to apply even more rigorous eligibility criteria. We also encourage future studies to systematically report the blinding of study personnel toward laboratory results and to rigorously control all statistical analyses for age, sex, BMI, smoking, and current levels of depression where applicable.
Taken together, the present review found the comorbidity between anxiety disorders and thyroid disorders was significant. This is supportive of the recommendation to routinely screen for thyroid disorders when treating patients with anxiety disorders (e.g., Bandelow et al., 2014) . Half of the studies supported the notion of subclinical thyroid dysfunction in that TSH responses to TRH administration were blunted and an inverse relationship was observed between self-reported anxiety levels and TSH. It is tempting to speculate that in some patients, anxiety and thyroid dysfunction partly emanate from shared etiopathogenetic factors, such as stress. However, the risk of bias assessment of this review clearly underscores the need for more high-quality studies prior to further investigation of this issue. Case-control designs including patients with different forms of anxiety and depression, and potentially other stress-related disorders presenting with bodily symptoms (e.g., somatic symptom disorder), seem particularly promising in this respect. Furthermore, the use of laboratory challenges mimicking real-life psychosocial stress (e.g., the
Trier Social Stress Test; Kirschbaum, Pirke, & Hellhammer, 1993) may prove an intriguing alternative to pharmacologically probing the HPT axis with standardized doses of exogenous TRH. We further believe that longitudinal epidemiological research is necessary at this stage to delineate the temporal order in which anxiety and (subclinical) thyroid disorders evolve over the course of development. Combining these approaches should allow for further progress to be made in unraveling the extent and meaning of thyroid dysfunction in anxiety disorders.
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